Are Opioids Needed to Treat Chronic Low Back Pain? A Review of Treatment Options and Analgesics in Development

References

• GBD. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1545–1602. doi:10.1016/S0140-6736(16)31678-6
   PubMed Web of Science ®Google Scholar
• NCHS. Health, United States, 2016: with chartbook on long-term trends in health. 2016;194–196. Available from: https://www.cdc.gov/nchs/data/hus/hus16.pdf
   Google Scholar
• Chou R, Shekelle P. Will this patient develop persistent disabling low back pain? JAMA. 2010;303(13):1295–1302. doi:10.1001/jama.2010.344
   PubMed Web of Science ®Google Scholar
• Herndon CM, Zoberi KS, Gardner BJ. Common questions about chronic low back pain. Am Fam Physician. 2015;91(10):708–714.
   PubMed Web of Science ®Google Scholar
• Shmagel A, Foley R, Ibrahim H. Epidemiology of chronic low back pain in US adults: data from the 2009–2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016;68(11):1688–1694. doi:10.1002/acr.v68.11
   PubMed Web of Science ®Google Scholar
• Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults - United States, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(36):1001–1006. doi:10.15585/mmwr.mm6736a2
   PubMed Web of Science ®Google Scholar
• Gore M, Sadosky A, Stacey BR, Tai KS, Leslie D. The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings. Spine (Phila Pa 1976). 2012;37(11):E668–677. doi:10.1097/BRS.0b013e318241e5de
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Ballestros K, Echko M, et al. The state of US health, 1990–2016: burden of diseases, injuries, and risk factors among US states. JAMA. 2018;319(14):1444–1472. doi:10.1001/jama.2018.0158
   PubMed Web of Science ®Google Scholar
• Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018;391(10137):2356–2367. doi:10.1016/S0140-6736(18)30480-X
   PubMed Web of Science ®Google Scholar
• Boden SD, Davis DO, Dina TS, Patronas NJ, Wiesel SW. Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. a prospective investigation. J Bone Joint Surg Am. 1990;72(3):403–408. doi:10.2106/00004623-199072030-00013
   PubMed Web of Science ®Google Scholar
• Aprill C, Bogduk N. High-intensity zone: a diagnostic sign of painful lumbar disc on magnetic resonance imaging. Br J Radiol. 1992;65(773):361–369. doi:10.1259/0007-1285-65-773-361
   PubMed Web of Science ®Google Scholar
• Kean Chen C, Nizar AJ. Prevalence of piriformis syndrome in chronic low back pain patients. A clinical diagnosis with modified FAIR test. Pain Pract. 2013;13(4):276–281. doi:10.1111/papr.2013.13.issue-4
   Web of Science ®Google Scholar
• Manniche C, Jordan A. 10 years of research: from ignoring Modic changes to considerations regarding treatment and prevention of low-grade disc infections. Future Sci OA. 2016;2(2):Fso117. doi:10.4155/fsoa-2016-0017
   Google Scholar
• Brinjikji W, Diehn FE, Jarvik JG, et al. MRI findings of disc degeneration are more prevalent in adults with low back pain than in asymptomatic controls: a systematic review and meta-analysis. AJNR Am J Neuroradiol. 2015;36(12):2394–2399. doi:10.3174/ajnr.A4498
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the american college of physicians. Ann Intern Med. 2017;166(7):514–530. doi:10.7326/M16-2367
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM. Using the CDC guideline and tools for opioid prescribing in patients with chronic pain. Am Fam Physician. 2016;93(12):970–972.
   Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49. doi:10.15585/mmwr.rr6501e1
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA. 2016;315(15):1624–1645. doi:10.1001/jama.2016.1464
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: american Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician. 2017;20(2s):S3–S92. doi:10.36076/ppj.2017.s92
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Buenaventura RM, Manchikanti KN, et al. Effectiveness of therapeutic lumbar transforaminal epidural steroid injections in managing lumbar spinal pain. Pain Physician. 2012;15(3):E199–245.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Vorobeychik Y, Wasserman R, et al. The effectiveness and risks of fluoroscopically guided lumbar interlaminar epidural steroid injections: a systematic review with comprehensive analysis of the published data. Pain Med. 2017;18(2):239–251. doi:10.1093/pm/pnw131
   PubMed Web of Science ®Google Scholar
• Thomson S. Failed back surgery syndrome - definition, epidemiology and demographics. Br J Pain. 2013;7(1):56–59. doi:10.1177/2049463713479096
   PubMedGoogle Scholar
• Chou R, Deyo R, Friedly J, et al. Nonpharmacologic therapies for low back pain: a systematic review for an American college of physicians clinical practice guideline. Ann Intern Med. 2017;166(7):493–505. doi:10.7326/M16-2459
   PubMed Web of Science ®Google Scholar
• Skelly AC, Chou R, Dettori JR, et al. Noninvasive nonpharmacological treatment for chronic pain: a systematic review. Comparative Effectiveness Review No. 209. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2015-000009-I). AHRQ Publication No 18-EHC013-EF. 2018. Available from: https://effectivehealthcare.ahrq.gov/topics/nonpharma-treatment-pain/research-2018. Accessed July 11, 2018.
   Google Scholar
• Wieland LS, Skoetz N, Pilkington K, Vempati R, D’adamo CR, Berman BM. Yoga treatment for chronic non-specific low back pain. Cochrane Database Syst Rev. 2017;1:Cd010671.
   PubMed Web of Science ®Google Scholar
• Yamato TP, Maher CG, Saragiotto BT, et al. Pilates for low back pain. Cochrane Database Syst Rev. 2015;7:Cd010265.
   Google Scholar
• Cherkin DC, Sherman KJ, Balderson BH, et al. Effect of mindfulness-based stress reduction vs cognitive behavioral therapy or usual care on back pain and functional limitations in adults with chronic low back pain: a randomized clinical trial. JAMA. 2016;315(12):1240–1249. doi:10.1001/jama.2016.2323
   PubMed Web of Science ®Google Scholar
• Coulter ID, Crawford C, Hurwitz EL, et al. Manipulation and mobilization for treating chronic low back pain: a systematic review and meta-analysis. Spine J. 2018;18(5):866–879. doi:10.1016/j.spinee.2018.01.013
   PubMed Web of Science ®Google Scholar
• Sun E, Moshfegh J, Rishel CA, Cook CE, Goode AP, George SZ. Association of early physical therapy with long-term opioid use among opioid-naive patients with musculoskeletal pain. JAMA Netw Open. 2018;1(8):e185909. doi:10.1001/jamanetworkopen.2018.5909
   PubMed Web of Science ®Google Scholar
• van Middelkoop M, Rubinstein SM, Kuijpers T, et al. A systematic review on the effectiveness of physical and rehabilitation interventions for chronic non-specific low back pain. Eur Spine J. 2011;20(1):19–39. doi:10.1007/s00586-010-1518-3
   PubMed Web of Science ®Google Scholar
• Cuenca-martinez F, Cortes-amador S, Espi-lopez GV. Effectiveness of classic physical therapy proposals for chronic non-specific low back pain: a literature review. Phys Ther Res. 2018;21(1):16–22. doi:10.1298/ptr.E9937
   PubMedGoogle Scholar
• Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American college of physicians clinical practice guideline. Ann Intern Med. 2017;166(7):480–492. doi:10.7326/M16-2458
   PubMed Web of Science ®Google Scholar
• Enthoven WT, Roelofs PD, Deyo RA, van Tulder MW, Koes BW. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016;2:Cd012087. doi:10.1002/14651858.CD004158.pub3
   PubMed Web of Science ®Google Scholar
• Enthoven WT, Roelofs PD, Koes BW. NSAIDs for chronic low back pain. JAMA. 2017;317(22):2327–2328. doi:10.1001/jama.2017.4571
   PubMed Web of Science ®Google Scholar
• Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976). 2010;35(13):E578–585. doi:10.1097/BRS.0b013e3181d3cef6
   Web of Science ®Google Scholar
• Skljarevski V, Ossanna M, Liu-seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol. 2009;16(9):1041–1048. doi:10.1111/ene.2009.16.issue-9
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain. 2010;11(12):1282–1290. doi:10.1016/j.jpain.2010.03.002
   PubMed Web of Science ®Google Scholar
• Konno S, Oda N, Ochiai T, Alev L. Randomized, double-blind, placebo-controlled Phase III trial of duloxetine monotherapy in japanese patients with chronic low back pain. Spine (Phila Pa 1976). 2016;41(22):1709–1717. doi:10.1097/BRS.0000000000001707
   PubMed Web of Science ®Google Scholar
• Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018;319(9):872–882. doi:10.1001/jama.2018.0899
   PubMed Web of Science ®Google Scholar
• Volkow ND, McLellan AT. Opioid abuse in chronic pain–misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253–1263. doi:10.1056/NEJMra1507771
   PubMed Web of Science ®Google Scholar
• Darnall BD, Juurlink D, Kerns RD, et al. International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. Pain Med. 2019;20(3):429–433. doi:10.1093/pm/pny228
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med. 2019;380(24):2285–2287. doi:10.1056/NEJMp1904190
   PubMed Web of Science ®Google Scholar
• Wen W, Sitar S, Lynch SY, He E, Ripa SR. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain. Expert Opin Pharmacother. 2015;16(11):1593–1606. doi:10.1517/14656566.2015.1060221
   PubMed Web of Science ®Google Scholar
• Rauck RL, Nalamachu S, Wild JE, et al. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. Pain Med. 2014;15(6):975–985. doi:10.1111/pme.12377
   PubMed Web of Science ®Google Scholar
• Hale ME, Laudadio C, Yang R, Narayana A, Malamut R. Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain. J Pain Res. 2015;8:623–636. doi:10.2147/JPR
   PubMed Web of Science ®Google Scholar
• Hale ME, Zimmerman TR, Eyal E, Malamut R. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain. J Opioid Manag. 2015;11(6):507–518. doi:10.5055/jom.2015.0304
   PubMedGoogle Scholar
• Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010;26(6):1505–1518. doi:10.1185/03007995.2010.484723
   PubMed Web of Science ®Google Scholar
• Rauck RL, Bookbinder SA, Bunker TR, et al. The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag. 2006;2(3):155–166. doi:10.5055/jom.2006.0025
   PubMedGoogle Scholar
• Rauck RL, Bookbinder SA, Bunker TR, et al. A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial. J Opioid Manag. 2006;2(6):325–328, 331–323. doi:10.5055/jom.2006.0048
   Google Scholar
• Katz N, Kopecky EA, O’connor M, Brown RH, Fleming AB. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain. 2015;156(12):2458–2467. doi:10.1097/j.pain.0000000000000315
   PubMed Web of Science ®Google Scholar
• Ueberall MA, Mueller-schwefe GH. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations. Curr Med Res Opin. 2015;31(7):1413–1429. doi:10.1185/03007995.2015.1047747
   PubMed Web of Science ®Google Scholar
• Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23(1):117–128. doi:10.1185/030079906X162692
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175–184. doi:10.1016/j.jpain.2006.09.011
   PubMed Web of Science ®Google Scholar
• Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain. 2005;6(1):21–28. doi:10.1016/j.jpain.2004.09.005
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee CS. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain. Clin Ther. 2013;35(11):1830–1840. doi:10.1016/j.clinthera.2013.09.017
   PubMed Web of Science ®Google Scholar
• Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N. Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. J Rheumatol. 2004;31(12):2454–2463.
   PubMed Web of Science ®Google Scholar
• Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. Clin Ther. 2003;25(4):1123–1141. doi:10.1016/S0149-2918(03)80071-1
   PubMed Web of Science ®Google Scholar
• Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain. 2011;12(11):1163–1173. doi:10.1016/j.jpain.2011.06.003
   PubMed Web of Science ®Google Scholar
• Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2011;42(6):903–917. doi:10.1016/j.jpainsymman.2011.04.006
   PubMed Web of Science ®Google Scholar
• Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther. 2010;32(5):844–860. doi:10.1016/j.clinthera.2010.04.018
   PubMed Web of Science ®Google Scholar
• Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med. 2016;128(1):1–11. doi:10.1080/00325481.2016.1128307
   PubMed Web of Science ®Google Scholar
• Buynak R, Rappaport SA, Rod K, et al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin Ther. 2015;37(11):2420–2438. doi:10.1016/j.clinthera.2015.08.014
   PubMed Web of Science ®Google Scholar
• Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11(11):1787–1804. doi:10.1517/14656566.2010.497720
   PubMed Web of Science ®Google Scholar
• Vorsanger GJ, Xiang J, Gana TJ, Pascual ML, Fleming RR. Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain. J Opioid Manag. 2008;4(2):87–97. doi:10.5055/jom.2008.0013
   PubMedGoogle Scholar
• Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163(20):2433–2445. doi:10.1001/archinte.163.20.2433
   PubMed Web of Science ®Google Scholar
• Meske DS, Lawal OD, Elder H, Langberg V, Paillard F, Katz N. Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials. J Pain Res. 2018;11:923–934. doi:10.2147/JPR
   PubMed Web of Science ®Google Scholar
• Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA. 2018;320(23):2448–2460. doi:10.1001/jama.2018.18472
   PubMed Web of Science ®Google Scholar
• Campbell J, King NB. “Unsettling circularity”: clinical trial enrichment and the evidentiary politics of chronic pain. BioSocieties. 2017;12(2):191–216. doi:10.1057/biosoc.2016.7
   Web of Science ®Google Scholar
• FDA. U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for industry: enrichment strategies for clinical trials to support approval of human drugs and biological products. 2012. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf. Accessed July 31, 2018.
   Google Scholar
• Gewandter JS, Dworkin RH, Turk DC, et al. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain. 2014;155(9):1683–1695. doi:10.1016/j.pain.2014.05.025
   PubMed Web of Science ®Google Scholar
• Yamato TP, Maher CG, Saragiotto BT, et al. Comparison of effect sizes between enriched and nonenriched trials of analgesics for chronic musculoskeletal pain: a systematic review. Br J Clin Pharmacol. 2017;83(11):2347–2355. doi:10.1111/bcp.v83.11
   Web of Science ®Google Scholar
• Furlan A, Chaparro LE, Irvin E, Mailis-gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag. 2011;16(5):337–351. doi:10.1155/2011/465281
   PubMed Web of Science ®Google Scholar
• Abdel Shaheed C, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(7):958–968. doi:10.1001/jamainternmed.2016.1251
   PubMed Web of Science ®Google Scholar
• Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT. A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther. 2018;7(1):13–21. doi:10.1007/s40122-018-0097-6
   PubMed Web of Science ®Google Scholar
• Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276–286. doi:10.7326/M14-2559
   PubMed Web of Science ®Google Scholar
• Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360–372. doi:10.1016/j.jpain.2007.11.014
   PubMed Web of Science ®Google Scholar
• Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432–442. doi:10.1111/j.1526-4637.2005.00072.x
   PubMed Web of Science ®Google Scholar
• Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671–681. doi:10.1016/j.jpain.2006.03.001
   PubMed Web of Science ®Google Scholar
• Pasternak GW. Molecular insights into mu opioid pharmacology: from the clinic to the bench. Clin J Pain. 2010;26(Suppl 10):S3–9. doi:10.1097/AJP.0b013e3181c49d2e
   PubMed Web of Science ®Google Scholar
• Centers For Disease C. Prevention Public Health Service USDOH, Human S. Guideline for prescribing opioids for chronic pain. J Pain Palliat Care Pharmacother. 2016;30(2):138–140. doi:10.3109/15360288.2016.1173761
   Google Scholar
• FDA. Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse. 2018. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm614110.htm. Accessed September 18, 2018.
   Google Scholar
• FDA. Abuse-deterrent opioid analgesics. 2018. Available from: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm600788.htm. Accessed October 10, 2018.
   Google Scholar
• Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - putting the potential benefits into perspective. N Engl J Med. 2017;376(22):2103–2105. doi:10.1056/NEJMp1701553
   PubMed Web of Science ®Google Scholar
• Lee YH, Brown DL, Chen HY. Current impact and application of abuse-deterrent opioid formulations in clinical practice. Pain Physician. 2017;20(7):E1003–E1023.
   PubMed Web of Science ®Google Scholar
• Hale ME, Moe D, Bond M, Gasior M, Malamut R. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. 2016;6(5):497–508. doi:10.2217/pmt-2015-0005
   PubMed Web of Science ®Google Scholar
• NIDA. National institute of drug abuse: overdose death rates. 2018. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Accessed January 25, 2019.
   Google Scholar
• Miyazaki T, Choi IY, Rubas W, et al. NKTR-181: a novel mu-opioid analgesic with inherently low abuse potential. J Pharmacol Exp Ther. 2017;363(1):104–113. doi:10.1124/jpet.117.243030
   PubMed Web of Science ®Google Scholar
• Comer SD, Ashworth JB, Sullivan MA, Vosburg SK, Saccone PA, Foltin RW. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag. 2009;5(4):203–212. doi:10.5055/jom.2009.0022
   PubMedGoogle Scholar
• Webster L, Henningfield J, Buchhalter AR, et al. Human abuse potential of the new opioid analgesic molecule NKTR-181 compared with oxycodone. Pain Med. 2018;19(2):307–318. doi:10.1093/pm/pnw344
   Web of Science ®Google Scholar
• Ge XS, Henningfield J, Siddhanti S, et al. Human abuse potential of oral NKTR-181 in recreational opioid users: a randomized, double-blind, crossover study. Pain Med. Submitted. 2018.
   Web of Science ®Google Scholar
• Ge XS, Lu L, Jobes J, et al. Abuse potential of NKTR-181 in recreational opioid users: results from a randomized, double-blind crossover oral study. Paper presented at: American College of Neuropsychopharmacology 56th Annual Meeting2017; Palm Springs, CA.
   Google Scholar
• Markman J, Gudin J, Rauck R, et al. SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain. Pain. 2019;160(6):1374–1382. doi:10.1097/j.pain.0000000000001517
   Web of Science ®Google Scholar
• Gudin J, Rauck R, Argoff C, et al. Long-term safety and tolerability of NKTR-181 in patients with moderate to severe chronic low back pain or chronic noncancer pain: a Phase 3 multicenter, open-label, 52-week study (SUMMIT-08 LTS). Pain Med. 2019. doi:10.1093/pm/pnz169
   Web of Science ®Google Scholar
• Christoph A, Eerdekens MH, Kok M, Volkers G, Freynhagen R. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain. 2017;158(9):1813–1824. doi:10.1097/j.pain.0000000000000986
   PubMed Web of Science ®Google Scholar
• Gohler K, Sokolowska M, Schoedel KA, et al. Assessment of the abuse potential of cebranopadol in nondependent recreational opioid users: a phase 1 randomized controlled study. J Clin Psychopharmacol. 2019;39(1):46–56. doi:10.1097/JCP.0000000000000995
   PubMed Web of Science ®Google Scholar
• Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature. 2000;408(6813):720–723. doi:10.1038/35047086
   PubMed Web of Science ®Google Scholar
• Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999;286(5449):2495–2498. doi:10.1126/science.286.5449.2495
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Webster L, Kuss M, et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the mu-opioid receptor, for the intravenous treatment of acute pain. Pain. 2016;157(1):264–272. doi:10.1097/j.pain.0000000000000363
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Skobieranda F, Soergel DG, Cook E, Burt DA, Singla N. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927–943. doi:10.2147/JPR.S171013
   PubMed Web of Science ®Google Scholar
• Singla NK, Skobieranda F, Soergel DG, et al. APOLLO-2: a randomized, placebo and active controlled Phase III study investigating oliceridine (TRV 130), a G Protein–biased ligand at the μ-opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract. 2019;19(7):715–731. doi:10.1111/papr.v19.7
   PubMed Web of Science ®Google Scholar
• Albert-vartanian A, Boyd MR, Hall AL, et al. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther. 2016;41(4):371–382. doi:10.1111/jcpt.2016.41.issue-4
   PubMed Web of Science ®Google Scholar
• Menzaghi F, Spencer R, Abrouk N, Lewis M, Chalmers D. (422) CR845, a peripheral kappa opioid, provides better pain relief with less nausea and vomiting than placebo in patients after bunionectomy. J Pain. 2015;16(4):S81. doi:10.1016/j.jpain.2015.01.341
   Web of Science ®Google Scholar
• Cara_Therapeutics. Cara therapeutics reports positive top-line data from adaptive phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgery. 2018. Available from: https://globenewswire.com/news-release/2018/06/27/1530177/0/en/Cara-Therapeutics-Reports-Positive-Top-Line-Data-from-Adaptive-Phase-2-3-Trial-of-I-V-CR845-in-Patients-Undergoing-Abdominal-Surgery.html. Accessed July 31, 2019.
   Google Scholar
• Phan NQ, Lotts T, Antal A, Bernhard JD, Stander S. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol. 2012;92(5):555–560. doi:10.2340/00015555-1353
   PubMed Web of Science ®Google Scholar
• Brust TF, Morgenweck J, Kim SA, et al. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal. 2016;9(456):ra117. doi:10.1126/scisignal.aai8441
   PubMed Web of Science ®Google Scholar
• Roques BP, Fournie-zaluski MC, Wurm M. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov. 2012;11(4):292–310. doi:10.1038/nrd3673
   PubMed Web of Science ®Google Scholar
• Raffa RB, Pergolizzi JV Jr., Taylor R Jr., Ossipov MH. Indirect-acting strategy of opioid action instead of direct receptor activation: dual-acting enkephalinase inhibitors (DENKIs). J Clin Pharm Ther. 2018;43(4):443–449. doi:10.1111/jcpt.2018.43.issue-4
   Web of Science ®Google Scholar
• Wurm M, Ouimet T, Marie N, et al. DENKI (Dual Enkephalinase Inhibitors), a New Class of Painkillers Devoid of Abuse Potential and of Opiate Side-Effects. Boston, MA: International Conference on Opioids (ICOO 2018); 2018.
   Google Scholar
• Godfrey L, Iannitelli A, Garrett NL, et al. Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. J Control Release. 2018;270:135–144. doi:10.1016/j.jconrel.2017.11.041
   PubMed Web of Science ®Google Scholar
• Gu ZH, Wang B, Kou ZZ, et al. Endomorphins: promising endogenous opioid peptides for the development of novel analgesics. Neurosignals. 2017;25(1):98–116. doi:10.1159/000484909
   Google Scholar
• Webster L, Schmidt WK. Dilemma of addiction and respiratory depression in the treatment of pain: a prototypical endomorphin as a new approach. Pain Med. 2019;pii:5511538.
   Google Scholar
• Cytogel. Cytogel Pharma announces receipt of FDA authorization to commence phase 2 development for its atypical opioid, CYT-1010. 2019. Available from: https://www.prnewswire.com/news-releases/cytogel-pharma-announces-receipt-of-fda-authorization-to-commence-phase-2–development-for-its-atypical-opioid-cyt-1010-300790012.html. Accessed July 31, 2019.
   Google Scholar
• Wang D, Sun X, Sadee W. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther. 2007;321(2):544–552. doi:10.1124/jpet.106.118810
   Web of Science ®Google Scholar
• Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. Clin Pharm. 1984;3(3):273–280.
   Google Scholar
• Verebey K, Mule SJ. Naltrexone pharmacology, pharmacokinetics, and metabolism: current status. Am J Drug Alcohol Abuse. 1975;2(3–4):357–363. doi:10.3109/00952997509005661
   Web of Science ®Google Scholar
• Galloway GP, Koch M, Cello R, Smith DE. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry. 2005;5:18. doi:10.1186/1471-244X-5-18
   PubMed Web of Science ®Google Scholar
• Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2
   PubMed Web of Science ®Google Scholar
• Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol. 2007;102(4):820–828. doi:10.1111/ajg.2007.102.issue-4
   PubMed Web of Science ®Google Scholar
• Gironi M, Martinelli-boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler. 2008;14(8):1076–1083. doi:10.1177/1352458508095828
   Web of Science ®Google Scholar
• Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest. 1995;13(6):561–566. doi:10.3109/07357909509024923
   PubMed Web of Science ®Google Scholar
• Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x
   PubMed Web of Science ®Google Scholar
• Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-frank J, Milligan ED, Maier SF, Norman Cousins Lecture. Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun. 2007;21(2):131–146. doi:10.1016/j.bbi.2006.10.011
   PubMed Web of Science ®Google Scholar
• Liu SL, Li YH, Shi GY, et al. A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol. 2006;48(9):1871–1879. doi:10.1016/j.jacc.2006.07.036
   PubMed Web of Science ®Google Scholar
• Ghai B, Bansal D, Hota D, Shah CS. Off-label, low-dose naltrexone for refractory chronic low back pain. Pain Med. 2014;15(5):883–884. doi:10.1111/pme.12345
   Web of Science ®Google Scholar